The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.72
Bid: 3.60
Ask: 3.84
Change: -0.10 (-2.62%)
Spread: 0.24 (6.667%)
Open: 3.82
High: 0.00
Low: 0.00
Prev. Close: 3.82
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Technology Update

6 Jun 2017 07:00

RNS Number : 2009H
Plant Health Care PLC
06 June 2017
 

6 June 2017

Plant Health Care plc(the "Company" ", "PHC" or "Plant Health Care")New Technology Update

Plant Health Care (AIM: PHC), a leading provider of novel patent-protected biological products to global agriculture markets, is pleased to provide the following update in relation to its New Technology business.

Highlights

- Evaluation of Innatus 3G continues to expand. The four major industry partners have increased the scale of their 2017 trials. Three other companies have signed evaluation agreements and are conducting field trials.

- A total of eight agreements have also now been signed concerning T-Rex 3G and Y-Max-3G.

- Strong progress continues within Plant Health Care on its capability to make, formulate and register PREtec peptides.

- The Company remains on track to deliver a revenue-generating licence by the end of 2017 and the first competitive licensing process in early 2018.

 

Innatus 3G

Four of the top six agrochemicals companies have been evaluating Innatus 3G since 2015. They are focused on three core agricultural benefits - yield increase, disease and nematode protection and drought resistance - mainly in the largest commercial crops corn (maize) and soybean. Building on their 2016 results, all are running trials of lead peptides from this platform in 2017.

By early 2017, three other companies had signed agreements to evaluate Innatus 3G. Their field trials, in other smaller crops, are underway in Europe and South America.

In recent weeks several partners have approached PHC with plans to expand their 2017 trials further. Of particular interest is the control of Asian Soybean Rust, a fungal disease which is a major threat to the soybean crop in Brazil. This disease has developed resistance to most conventional fungicides. Innatus 3G peptides work very differently, and when sprayed in mixtures with standard fungicides, they have shown significantly improved disease control in PHC's trials. This has the potential to increase the effectiveness and extend the commercial life of those established products.

T-Rex 3G and Y-Max 3G

PHC's new technology platforms, T-Rex 3G and Y-Max 3G, were first presented to the industry in 2016. T-Rex 3G is a class of signal peptides optimised for nematode suppression, while Y-Max 3G peptides are biostimulants which increase yield.

A total of eight companies have so far signed up to evaluate one or both of these new platforms, including the majors who are evaluating Innatus 3G. Trials are in progress in three continents in a range of crops, with two lead peptides from each of T-Rex 3G and Y-Max 3G. The majors are focused mainly on corn and soybean, while others are working on a wider range of crops.

The Company continues to aim to secure the first revenue-generating licence of one of its PREtec technologies in 2017.

PHC's product development capability

Plant Health Care has increased its product development activity. This includes substantially expanding its own 2017 field trials and contract testing programme. But because partners' evaluations of PREtec peptides are on a much larger scale than in 2016, collectively they are spending many times more than the Company is.

Plant Health Care's work on the physical stability of peptides in formulations and their compatibility with agrochemicals continues to show promising results. We expect the most cost-effective means of peptide manufacture to be by fermentation, and laboratory scale production trials are on track. The first lead peptides produced by fermentation are being evaluated and will shortly be entering field trials.

 

Chris Richards, Executive Chairman & Interim CEO, said "Momentum continues to build. As we approach the expected 2018 date for licensing of first rights to Innatus 3G, partners are stepping up their evaluations. Our lead peptides from each platform are performing well in independent trials, carried out by our partners."

"It is a great vote of confidence in our proprietary technology. Every one of our initial partners is now testing one or both of T-Rex 3G and Y-Max 3G, alongside Innatus 3G. Our new partners are expanding the range of crops to which our products can bring benefits. This year, partners will spend much more than us on evaluating our proprietary technology."

"We are well positioned for the first licensing of our PREtec technology by the end of 2017, with competitive licensing of Innatus 3G to start in early 2018."

 

Enquiries:

Plant Health Care plc

Dr Chris Richards, Executive Chairman and Interim CEO

Tel: +44 (0) 18 3788 0083

Liberum Capital - Nomad and Broker

Clayton Bush / Chris Clarke

Tel: +44 (0) 20 3100 2000

Company website: www.planthealthcare.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RESUGUWCQUPMGMA
Date   Source Headline
9th May 20131:20 pmRNSResult of AGM
7th May 201310:00 amRNSDirector/PDMR Shareholding
3rd May 20137:00 amRNSDirector/PDMR Shareholding
1st May 20137:00 amRNSDirector/PDMR Shareholding
1st May 20137:00 amRNSTotal Voting Rights
25th Apr 20137:00 amRNSPHC and Arysta LifeScience sign license agreement
19th Apr 20133:30 pmRNSTR-1 Notification of Major Interest in Shares
18th Apr 20133:33 pmRNSTR-1 Notification of Major Interest in Shares
18th Apr 20133:31 pmRNSTR-1 Notification of Major Interest in Shares
18th Apr 20133:31 pmRNSTR-1 Notification of Major Interest in Shares
16th Apr 20138:23 amRNSRe. Investment
15th Apr 20131:30 pmRNSResult of General Meeting
8th Apr 20135:45 pmRNSPublication of Annual Report and Notice of AGM
2nd Apr 20137:00 amRNSConfirmation of Board Changes
27th Mar 20137:00 amRNSPosting of Circular to Shareholders
26th Mar 20134:19 pmRNSBoard Changes
26th Mar 20134:19 pmRNSPlacing and Subscription
26th Mar 20134:18 pmRNSFinal Results
20th Mar 201311:35 amRNSPHC reaches milestone agreement with Germains
11th Mar 20137:00 amRNSMarket Update
19th Feb 20135:45 pmRNSBlock Listing Six-Monthly Return
24th Jan 20139:30 amRNSHarpin field trials results
18th Jan 20135:00 pmRNSNotification of Major Interest in Shares
10th Jan 201312:45 pmRNSTrading Update
31st Dec 201212:25 pmRNSTotal Voting Rights
30th Nov 201211:45 amRNSTotal Voting Rights
2nd Nov 201212:15 pmRNSNotification of Major Interest in Shares
23rd Oct 20127:00 amRNSNotification of Major Interest in Shares
22nd Oct 20122:00 pmRNSNotification of Major Interest in Shares
19th Oct 20123:10 pmRNSNotification of Major Interest in Shares
9th Oct 20127:00 amRNSStrong uptake of new product
8th Oct 20127:00 amRNSNotification of Major Interest In Shares
13th Sep 20127:00 amRNSSignificant progress in SA 2013 maize crop season
31st Aug 20125:00 pmRNSTotal Voting Rights
30th Aug 20122:47 pmRNSHolding(s) in Company
28th Aug 20129:40 amRNSPosting of Interim Report
24th Aug 20122:30 pmRNSDirector/PDMR Shareholding
20th Aug 201212:45 pmRNSAIM Blocklisting Interim Return
20th Aug 20127:00 amRNSHalf Yearly Report
14th Aug 20127:00 amRNSHolding(s) in Company
1st Aug 201212:15 pmRNSDirectorate Change
30th Jul 201212:15 pmRNSNotification of Major Interest in Shares
27th Jul 20127:00 amRNSPotato yield increased through PHC's Harpin
18th Jul 20127:00 amRNSHolding(s) in Company
17th Jul 20127:00 amRNSHolding(s) in Company
28th Jun 20127:00 amRNSHolding(s) in Company
17th May 20127:00 amRNSResearch cooperation with University of Arkansas
3rd May 201212:00 pmRNSHolding(s) in Company
1st May 20125:00 pmRNSTotal Voting Rights
27th Apr 201211:49 amRNSResearch Agreement with Arysta LifeScience

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.